Avak Kahvejian

Avak Kahvejian, Ph.D. is a life sciences inventor, entrepreneur, and CEO. Since 2011, he has been a partner at Flagship Pioneering, where he leads a team to invent and launch new therapeutic platforms. His work has led to the creation of multiple high-value public and private companies including Seres Therapeutics (NASDAQ: MCRB); the first microbiome therapy platform; Rubius Therapeutics (NASDAQ: RUBY); developing Red Cell Therapeutics, engineered red blood cells capable of providing potent and prolonged therapy for rare diseases, cancer, and autoimmunity; Codiak BioSciences (developing engineered exosome therapeutics as cancer treatments); Cygnal Therapeutics (pioneering new drugs that target neuronal pathways for the treatment of cancer, and autoimmune/inflammation disorders); Ring Therapeutics (revolutionizing gene therapy with its commensal virome platform); Cellarity (designing medicines against the cell as opposed to a single molecular target); Laronde (pioneering endless RNA – eRNA™ – a new class of programmable medicines capable of expressing therapeutic proteins inside the body); and Generate Biomedicines (pioneering Generative Biology™ to create breakthrough medicines).